LITESPARK-001: what clinicians are saying
belzutifan in advanced solid tumors · NCT02974738 ↗ · Phase 1 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The clinicians cited read LITESPARK-001 as supporting further development because disease control persisted despite prior treatment. A medical oncologist described in the sources as presenting the results cautions against overinterpreting progression-free survival and hopes biomarker studies will explain variable responses. A urologist favors cabozantinib over everolimus for subsequent testing, whereas medical oncologists consider everolimus defensible after cabozantinib or axitinib. Comparative advantages in benefit or safety remain unproven.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 87 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. Late-line ccRCC: most speakers highlight responses; a clinician flags single-arm PFS
5 of the report's 10 cited clinicians · 27 statements from 6 speakers in 13 sources, 5 of them podcasts or videos · 21 passages
Limitations recorded: 3.
Draws on: Population and setting, Safety and tolerability, Design and conduct, The comparison.
02. Belzutifan safety: how speakers weigh anemia, hypoxia and manageability
3 of the report's 10 cited clinicians · 27 statements from 4 speakers in 11 sources, 6 of them podcasts or videos · 20 passages
Limitations recorded: 6.
Draws on: Safety and tolerability, The comparison, Primary endpoint: maximum tolerated dose (MTD), Population and setting, Design and conduct.
03. HIF-2 targeting: a clinician sees proof of principle but hopes for biomarker work
1 of the report's 10 cited clinicians · 14 statements from 1 speaker in 6 sources, 4 of them podcasts or videos · 8 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Safety and tolerability, Design and conduct.
04. Everolimus control: most speakers question it; some see prior-therapy logic
4 of the report's 10 cited clinicians · 11 statements from 7 speakers in 4 sources, 2 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Beyond the trial population
05. Belzutifan: what speakers say
4 of the report's 10 cited clinicians · 14 statements from 5 speakers in 8 sources, 5 of them podcasts or videos · 12 passages
Limitations recorded: 4.
06. XmAb819: what speakers say
No named clinician · accounts and unnamed speakers · 2 statements in 1 source · 1 passage
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
5 of the report's 10 cited clinicians
Late-line ccRCC: most speakers highlight responses; a clinician flags single-arm PFS
27 statements from 6 speakers in 13 sources, 5 of them podcasts or videos
4 of the 6 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician flags single-arm PFS”
- 27
- statements
- 21
- passages
- 13
- sources
- 6
- speakers
What the statements areViews 17Questions and uncertainty 0Clinical experience 1Comparisons 1Restated results and context 8Statement-to-passage links (a passage can back several statements)Supporting a statement 31Giving context 2Recorded with the findingLimitations: 3
6 posts and articles · 5 podcasts and video · 2 publications
Draws on: Population and setting, Safety and tolerability, Design and conduct, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 6 findings and 12 of the 87 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MTD, maximum tolerated dose; NPI, National Provider Identifier, the US registry number for clinicians; PFS, progression-free survival; RCC, renal cell carcinoma.
The full LITESPARK-001 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say remains uncertain when interpreting PFS with belzutifan in heavily pretreated advanced clear-cell RCC from the single-arm LITESPARK-001 study?
From finding F1 (27 statements from 6 speakers in 13 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 26commentary sources screened
- 16sources cited by verified statements
- 14named in screened sources
- 14speakers cited in the report
- 14cited speakers with a verified identity
10 cited clinicians, speakers with a confirmed clinical role, of them 10 physicians. By role and specialty:
- 6 physician, Medical oncology
- 2 physician, specialty not confirmed
- 1 physician, Hematology and oncology
- 1 physician, Urology
Also in the sources: 1 organizational or shared account, not counted as people.
- 87verified statements, each linked to its source
- 45of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 87 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 10 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 16 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: maximum tolerated dose (MTD) | 3 | 1 |
| Population and setting | 7 | 5 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 6 | 5 |
| Safety and tolerability | 17 | 8 |
| Design and conduct | 6 | 4 |
| Activity, durability and the importance of prior treatment burden | 21 | 11 |
| Target rationale, scientific novelty and unresolved response or resistance | 13 | 5 |
| The subsequent phase III comparator debate | 10 | 4 |
| Post-IO positioning, combination development and research engagement | 13 | 6 |
| LITESPARK-013 as later dose-evaluation context | 3 | 1 |
| Use of the early cohort as a benchmark and questions after belzutifan exposure | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
87 verified statements from 16 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 39 statements · 45% | ||||
| YouTube | 35 | 5 | 5 | |
| X videos | 4 | 1 | 1 | |
| Posts · 33 statements · 38% | ||||
| X threads | 33 | 8 | 20 | |
| Primary sources · 15 statements · 17%cited for context, not screened | ||||
| Publications | 15 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 5 / quarter
- Screened window
- Jun 1, 2018 → Oct 20, 2026
- Cited window
- Jun 1, 2018 → Oct 20, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
- Registry
- NCT02974738
- Study IDs
- 6482-001 · PT2977-101 (Pelaton Study ID) · MK-6482-001 (MSD)
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Design
- Phase 1 · Interventional, non randomized, single group
- Status
- Active, not recruiting
- Enrollment
- 120 actual
- Registered
- 2016-11-28
- Start
- 2016-12-07 actual
- Primary completion
- 2018-01-12 actual
- Primary endpoint
- maximum tolerated dose (MTD)
- Interventions
- 1 registered
More on: Advanced solid tumors, Renal cell carcinoma, belzutifan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 38 sources about other trials or topics are not included.
- Most substantive views concern previously treated or refractory clear-cell RCC. They cannot establish how clinicians interpret the trial's other solid-tumor or glioblastoma populations.
- Several accounts discuss the clinical setting and intervention without naming LITESPARK-001. Their views are preserved as attributed context rather than automatically treated as this trial's results.
Show all 11 known gaps +Fewer −
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Different dates, follow-up durations, adverse-event definitions and treatment-attribution categories limit direct comparison across reports. They do not by themselves establish a change in opinion or a contradiction.
- Early phase I/II activity and observational toxicity comparisons do not establish randomized efficacy or safety advantages. Personal long-duration treatment examples are not cohort medians.
- The subsequent phase III comparator debate, LITESPARK-013 dose comparison, combination studies and post-belzutifan sequencing arguments concern separate development questions and must not be assigned to LITESPARK-001's own arms or outcomes.
- No standalone protocol or exact belzutifan product label was reviewed. Supportive-care descriptions are study-management accounts, not a complete prescribing or routine-care assessment.
- Multiple posts, relays or publications may repeat the same underlying presentation or data and should not be counted as independent HCP agreement.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. LITESPARK-001 (NCT02974738): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/litespark-001-nct02974738
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "LITESPARK-001" (NCT02974738), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "litespark-001-nct02974738". If you cannot make requests, read https://www.erudio.com/reports/litespark-001-nct02974738.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT02974738", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT02974738 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/litespark-001-nct02974738.json
curl https://www.erudio.com/reports/litespark-001-nct02974738.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "litespark-001-nct02974738" })release 3ac35ab5d4e066e1e11e68f6838e01ebdf4184145ca831aea924c999bb0c5e32
Questions
How much does the LITESPARK-001 report cost?
One edition costs $750 (Focused · 87 verified statements · 45 from 10 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the LITESPARK-001 report cover?
87 statements from 16 sources (6 videos, 8 posts, 2 papers), 45 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the LITESPARK-001 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "litespark-001-nct02974738" }) previews it and create_order({ "report": "litespark-001-nct02974738", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the LITESPARK-001 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.